186 related articles for article (PubMed ID: 37321529)
1. Ultrasound stiffness and perfusion markers correlate with tumor volume responses to immunotherapy.
Voutouri C; Mpekris F; Panagi M; Krolak C; Michael C; Martin JD; Averkiou MA; Stylianopoulos T
Acta Biomater; 2023 Sep; 167():121-134. PubMed ID: 37321529
[TBL] [Abstract][Full Text] [Related]
2. Pirfenidone-Loaded Polymeric Micelles as an Effective Mechanotherapeutic to Potentiate Immunotherapy in Mouse Tumor Models.
Mpekris F; Papaphilippou PC; Panagi M; Voutouri C; Michael C; Charalambous A; Marinov Dinev M; Katsioloudi A; Prokopi-Demetriades M; Anayiotos A; Cabral H; Krasia-Christoforou T; Stylianopoulos T
ACS Nano; 2023 Dec; 17(24):24654-24667. PubMed ID: 38054429
[TBL] [Abstract][Full Text] [Related]
3. A synergistic approach for modulating the tumor microenvironment to enhance nano-immunotherapy in sarcomas.
Mpekris F; Panagi M; Charalambous A; Voutouri C; Michael C; Papoui A; Stylianopoulos T
Neoplasia; 2024 May; 51():100990. PubMed ID: 38520790
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound Shear Wave Elastography for Liver Disease. A Critical Appraisal of the Many Actors on the Stage.
Piscaglia F; Salvatore V; Mulazzani L; Cantisani V; Schiavone C
Ultraschall Med; 2016 Feb; 37(1):1-5. PubMed ID: 26871407
[TBL] [Abstract][Full Text] [Related]
5. Tumor Elastography and Its Association with Collagen and the Tumor Microenvironment.
Riegler J; Labyed Y; Rosenzweig S; Javinal V; Castiglioni A; Dominguez CX; Long JE; Li Q; Sandoval W; Junttila MR; Turley SJ; Schartner J; Carano RAD
Clin Cancer Res; 2018 Sep; 24(18):4455-4467. PubMed ID: 29798909
[No Abstract] [Full Text] [Related]
6. Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates.
Seyhan AA; Carini C
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613491
[TBL] [Abstract][Full Text] [Related]
7. Nanomechanical properties of solid tumors as treatment monitoring biomarkers.
Stylianou A; Mpekris F; Voutouri C; Papoui A; Constantinidou A; Kitiris E; Kailides M; Stylianopoulos T
Acta Biomater; 2022 Dec; 154():324-334. PubMed ID: 36244596
[TBL] [Abstract][Full Text] [Related]
8. Machine learning analysis reveals tumor stiffness and hypoperfusion as biomarkers predictive of cancer treatment efficacy.
Englezos D; Voutouri C; Stylianopoulos T
Transl Oncol; 2024 Jun; 44():101944. PubMed ID: 38552284
[TBL] [Abstract][Full Text] [Related]
9. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
10. Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.
Sinha N; Sinha S; Valero C; Schäffer AA; Aldape K; Litchfield K; Chan TA; Morris LGT; Ruppin E
Cancer Res; 2022 Jun; 82(11):2076-2083. PubMed ID: 35385572
[TBL] [Abstract][Full Text] [Related]
11. Combining microenvironment normalization strategies to improve cancer immunotherapy.
Mpekris F; Voutouri C; Baish JW; Duda DG; Munn LL; Stylianopoulos T; Jain RK
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3728-3737. PubMed ID: 32015113
[TBL] [Abstract][Full Text] [Related]
12. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
13. Network-based machine learning approach to predict immunotherapy response in cancer patients.
Kong J; Ha D; Lee J; Kim I; Park M; Im SH; Shin K; Kim S
Nat Commun; 2022 Jun; 13(1):3703. PubMed ID: 35764641
[TBL] [Abstract][Full Text] [Related]
14. Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy.
Mpekris F; Voutouri C; Panagi M; Baish JW; Jain RK; Stylianopoulos T
J Control Release; 2022 May; 345():190-199. PubMed ID: 35271911
[TBL] [Abstract][Full Text] [Related]
15. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
Long J; Wang D; Wang A; Chen P; Lin Y; Bian J; Yang X; Zheng M; Zhang H; Zheng Y; Sang X; Zhao H
Genome Med; 2022 Feb; 14(1):20. PubMed ID: 35197093
[TBL] [Abstract][Full Text] [Related]
16. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.
Petrova V; Arkhypov I; Weber R; Groth C; Altevogt P; Utikal J; Umansky V
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235439
[TBL] [Abstract][Full Text] [Related]
17. NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.
Li H; Zhang Q; Duan Q; Tan Y; Sun T; Qi C
Front Immunol; 2022; 13():894110. PubMed ID: 35967450
[TBL] [Abstract][Full Text] [Related]
18. Tumor stiffness measured by shear wave elastography correlates with tumor hypoxia as well as histologic biomarkers in breast cancer.
Yoo J; Seo BK; Park EK; Kwon M; Jeong H; Cho KR; Woo OH; Song SE; Cha J
Cancer Imaging; 2020 Dec; 20(1):85. PubMed ID: 33256820
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors for the treatment of melanoma.
Sabbatino F; Liguori L; Pepe S; Ferrone S
Expert Opin Biol Ther; 2022 May; 22(5):563-576. PubMed ID: 35130816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]